HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $19
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $19
HC Wainwright & Co.維持對Relay Therapeutics的買入,將目標價下調至19美元
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $33 to $19.
HC Wainwright & Co. 分析師羅伯特·伯恩斯維持Relay Therapeutics(納斯達克股票代碼:RLAY)的買入,並將目標股價從33美元下調至19美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。